-
CIT Serves as Sole Lead Arranger on $43 Million Financing for Portfolio of Medical Office Buildings
NEW YORK, Sept. 1, 2021 /PRNewswire/ — CIT Group Inc. (NYSE: CIT) today announced that its Healthcare Finance business served as sole lead arranger on a loan of about $43 million to finance the acquisition of a portfolio of medical office buildings in Florida and Arizona. The portfolio, acquired by Cypress West Partners, consists of 14 medical office buildings encompassing nearly 150,000 square feet of rentable space. Ten of the facilities are located in Arizona and four are in Florida. “This portfolio consists of modern, well-designed and efficient facilities in attractive locations to support the medical needs … Read more
-
Genome Medical Announces Acquisition of GeneMatters and Closing of $60 Million Series C Financing
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genome Medical, the leading nationwide genomic care delivery company, today announced that it will acquire GeneMatters, a telehealth genetic counseling and software solutions company. Simultaneously, the company announced the closing of a $60 million Series C financing to accelerate commercial traction and advance its mission of transforming health care for all through genomic medicine. These strategic initiatives solidify its position as the preeminent technology-enabled provider of genetic health services and genomic insights. “The addition of GeneMatters, along with our Series C financing, propels us into the next phase of commercial growth and … Read more
You May Also Like
Women’s health app Flo picks up $50M in fresh funding to fuel R&D, rapid growth
Renovacor, Inc. Closes Its Business Combination with Chardan Healthcare Acquisition 2 Corp. and Will Begin Trading on the New York Stock Exchange
CIT Serves as Sole Lead Arranger on $43 Million Financing for Portfolio of Medical Office Buildings
-
ADC Therapeutics Enters Into a Financing Agreement with HealthCare Royalty for Up to $325 Million
ADCT sells capped royalty interest on ZYNLONTATM and Cami for $225 million upon closing with an additional $100 million in potential near-term milestone payments Royalty of 7% terminates upon payment of 2.25x to 2.50x the purchase price Proceeds to be used for continued development and commercialization of ZYNLONTATM and Cami LAUSANNE, Switzerland, August 26, 2021–(BUSINESS WIRE)–ADC Therapeutics SA (NYSE:ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological malignancies and solid tumors, today announced it had entered into a royalty purchase agreement with HealthCare Royalty Partners (HealthCare Royalty).… Read more
You May Also Like
Telehealth Startup Antidote Health Secures $12 mln In Seed Funding
Women’s health app Flo picks up $50M in fresh funding to fuel R&D, rapid growth
Renovacor, Inc. Closes Its Business Combination with Chardan Healthcare Acquisition 2 Corp. and Will Begin Trading on the New York Stock Exchange
